Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024
Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024
CINCINNATI--(BUSINESS WIRE)--Jun. 26, 2024-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will host a conference call the following morning, Tuesday, July 23, 2024, at 9:00 a.m. ET to discuss these results.
美迪康（medpace）控股有限公司（Nasdaq：MEDP）宣布将于2024年7月22日（周一）收盘后发布2024年第二季度财务业绩，并于2024年7月23日（周二）上午9:00（美国东部时间）召开电话会议，讨论这些结果。
To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
如需参加电话会议，有兴趣的各方必须提前注册，单击链接即可。虽然这不是必需的，但建议您提前10分钟加入该活动。注册后，所有电话参与者都将收到一封确认电子邮件，详细介绍如何参加电话会议，包括拨入号码以及可用于访问电话会议的唯一PIN码。此链接要通过网络广播访问电话会议，请访问medpace的“投资者”部分的网站investor.medpace.com。电话会议回放将在会议结束约一小时后在同一网站上提供。
To access the conference call via webcast, visit the "Investors" section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
要在电话会议开始前通过“投资者”部分的medpace网站获得补充幻灯片演示文稿。investor.medpace.com电话会议的网络广播回放将在会议结束约一小时后在同一网站上提供。
A supplemental slide presentation will also be available at the "Investors" section of Medpace's website prior to the start of the call.
美迪康是一家全球范围内提供一流科研及研发服务的医疗组织（CRO），其业务范围覆盖生物技术、制药和医疗设备等行业，致力于通过高科技及严谨的运营方式，在所有主要领域，包括肿瘤学、心脏病学、代谢病学、内分泌学、中枢神经系统和抗病毒及抗感染等领域整合监管和治疗专业知识，以加速全球安全有效的医学治疗方案开发。总部位于俄亥俄州辛辛那提市，截至2024年3月31日，美迪康在42个国家拥有约5,800名员工。
About Medpace
关于Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 42 countries as of March 31, 2024.
Medpace是一家以科学为驱动，全球范围内提供I-IV临床开发服务的全方位临床合同研究组织（CRO），为生物技术、制药和医疗器械行业提供服务。Medpace的使命是通过高科技和严谨的运营方法加快全球安全有效医疗疗法的开发，利用所有主要领域的监管和治疗专业知识，包括肿瘤、心脏病学、代谢疾病、内分泌学、中枢神经系统和抗病毒和抗感染。总部位于俄亥俄州辛辛那提市，截至2024年3月31日，Medpace在42个国家拥有约5800名员工。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626082979/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240626082979/en/
Investor Contact:
Lauren Morris
513.579.9911 x11994
l.morris@medpace.com
投资者联系：
Lauren Morris
513.579.9911 x11994
l.morris@medpace.com
Media Contact:
Julie Hopkins
513.579.9911 x12627
j.hopkins@medpace.com
媒体联系人：
Julie Hopkins
513.579.9911 x12627
j.hopkins@medpace.com
Source: Medpace Holdings, Inc.
资讯来源：美迪康控股有限公司。